Skip to content
Pergolide
Permax (pergolide) is a small molecule pharmaceutical. Pergolide was first approved as Permax on 1988-12-30. It is used to treat parkinson disease and tourette syndrome in the USA. It is known to target D(1B) dopamine receptor, 5-hydroxytryptamine receptor 1D, alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, D(3) dopamine receptor, D(1A) dopamine receptor, alpha-2C adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2A, D(4) dopamine receptor, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pergolide mesylate
Tradename
Company
Number
Date
Products
PERMAXBausch Health CompaniesN-019385 DISCN1988-12-30
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
tourette syndromeEFO_0004895D005879F95.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04B: Dopaminergic agents
— N04BC: Dopamine agonists
— N04BC02: Pergolide
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePERGOLIDE
INNpergolide
Description
Pergolide is a diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. It has a role as an antiparkinson drug and a dopamine agonist. It is a diamine, an organic heterotetracyclic compound and a methyl sulfide. It is a conjugate base of a pergolide(1+).
Classification
Small molecule
Drug classergot alkaloid deriviatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Identifiers
PDB—
CAS-ID66104-22-1
RxCUI8047
ChEMBL IDCHEMBL531
ChEBI ID63617
PubChem CID47811
DrugBankDB01186
UNII ID24MJ822NZ9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
DRD5
DRD5
HTR1D
HTR1D
ADRA2B
ADRA2B
ADRA2A
ADRA2A
DRD3
DRD3
DRD1
DRD1
ADRA2C
ADRA2C
DRD2
DRD2
HTR2B
HTR2B
HTR2A
HTR2A
DRD4
DRD4
HTR2C
HTR2C
HTR1A
HTR1A
HTR1B
HTR1B
HTR7
HTR7
HTR6
HTR6
Organism
Homo sapiens
Gene name
DRD5
Gene synonyms
DRD1B, DRD1L2
NCBI Gene ID
1816
Protein name
D(1B) dopamine receptor
Protein synonyms
D(5) dopamine receptor, D1beta dopamine receptor, Dopamine D5 receptor, dopamine receptor D1B
Uniprot ID
Q8NEQ8
Mouse ortholog
Drd5 (13492)
D(1B) dopamine receptor (Q8BLD9)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,121 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details